Progression of heart failure was suppressed by inhibition of apoptosis signal-regulating kinase 1 via transcoronary gene transfer

被引:39
作者
Hikoso, Shungo
Ikeda, Yasuhiro
Yamaguchi, Osamu
Takeda, Toshihiro
Higuchi, Yoshiharu
Hirotani, Shinichi
Kashiwase, Kazunori
Yamada, Michio
Asahi, Michio
Matsumura, Yasushi
Nishida, Kazuhiko
Matsuzaki, Masunori
Hori, Masatsugu
Otsu, Kinya
机构
[1] Osaka Univ, Grad Sch Med, Dept Cardiovasc Med, Suita, Osaka, Japan
[2] Osaka Univ, Grad Sch Med, Dept Biochem, Suita, Osaka, Japan
[3] Osaka Univ, Grad Sch Med, Dept Med Informat Sci, Suita, Osaka, Japan
[4] Yamaguchi Univ, Grad Sch Med, Dept Mol Cardiovasc Biol, Ube, Yamaguchi 755, Japan
[5] Yamaguchi Univ, Grad Sch Med, Dept Med & Clin Sci, Ube, Yamaguchi 755, Japan
关键词
CARDIAC DYSFUNCTION; DELTA-SARCOGLYCAN; DYSTROPHIN; PROTEINS; SCHEME; DEATH;
D O I
10.1016/j.jacc.2007.03.053
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives We examined whether the inhibition of apoptosis signal-regulating kinase 1 (ASK1) would attenuate the progression of heart failure in TO-2 hamsters with hereditary dilated cardiomyopathy. Background Heart failure remains the leading cause of mortality and requires novel therapies targeting the biologically relevant processes within cardiomyocytes that lead to cell death. Apoptosis signal-regulating kinase 1 is a key signaling molecule for cardiomyocyte death. Methods We generated recombinant adeno-associated virus (rAAV) expressing an N-terminal truncated form of the dominant-negative mutant of ASK1 (ASK Delta N(KR)). TO-2 hamsters were subjected to an in vivo rAAV transcoronary transfer. Results ASK Delta N(KR) retained its dominant-negative activity in vitro. The rAAV expressing ASK Delta N(KR) treatment inhibited ASK1 activation in the hamster hearts and suppressed progression of ventricular remodeling such as chamber dilation, impairment of contractile and relaxation functions, and fibrosis. Inhibition of ASK1 reduced the number of apoptotic cells and selectively attenuated c-Jun NH2-terminal kinase activation. Although the deficiency of delta-sarcoglycan, a genetic defect in the hamster, leads to the degradation of dystrophin, the treatment significantly protected hearts from this degradation, probably by inhibiting calpain activation. Conclusions Apoptosis signal-regulating kinase I is involved in the pathogenesis of heart failure progression, mediated through c-Jun NH2-terminal kinase-mediated apoptosis and calpain-dependent dystrophin cleavage, and may be a therapeutic target to treat patients with heart failure.
引用
收藏
页码:453 / 462
页数:10
相关论文
共 22 条
  • [11] Altered membrane proteins and permeability correlate with cardiac dysfunction in cardiomyopathic hamsters
    Ikeda, Y
    Martone, M
    Gu, YS
    Hoshijima, M
    Thor, A
    Oh, SS
    Peterson, KL
    Ross, J
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2000, 278 (04): : H1362 - H1370
  • [12] A novel mechanism of myocyte degeneration involving the Ca2+-permeable growth factor-regulated channel
    Iwata, Y
    Katanosaka, Y
    Arai, Y
    Komamura, K
    Miyatake, K
    Shigekawa, M
    [J]. JOURNAL OF CELL BIOLOGY, 2003, 161 (05) : 957 - 967
  • [13] A novel scheme of dystrophin disruption for the progression of advanced heart failure
    Kawada, T
    Masui, F
    Tezuka, A
    Ebisawa, T
    Kumagai, H
    Nakazawa, M
    Toyo-oka, T
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2005, 1751 (01): : 73 - 81
  • [14] Intracellular calcium level required for calpain activation in a single myocardial cell
    Matsumura, Y
    Saeki, E
    Otsu, K
    Morita, T
    Takeda, H
    Kuzuya, T
    Hori, M
    Kusuoka, H
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2001, 33 (06) : 1133 - 1142
  • [15] Controversies in Cardiology 4 - Controversies in ventricular remodelling
    Opie, LH
    Commerford, PJ
    Gersh, BJ
    Pfeffer, MA
    [J]. LANCET, 2006, 367 (9507) : 356 - 367
  • [16] Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: An animal model of disrupted dystrophin-associated glycoprotein complex
    Sakamoto, A
    Ono, K
    Abe, M
    Jasmin, G
    Eki, T
    Murakami, Y
    Masaki, T
    Toyooka, T
    Hanaoka, F
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (25) : 13873 - 13878
  • [17] CALPAINS ARE ACTIVATED IN NECROTIC FIBERS FROM MDX DYSTROPHIC MICE
    SPENCER, MJ
    CROALL, DE
    TIDBALL, JG
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (18) : 10909 - 10914
  • [18] Translocation and cleavage of myocardial dystrophin as a common pathway to advanced heart failure: A scheme for the progression of cardiac dysfunction
    Toyo-Oka, T
    Kawada, T
    Nakata, J
    Xie, H
    Urabe, M
    Masui, F
    Ebisawa, T
    Tezuka, A
    Iwasawa, K
    Nakajima, T
    Uehara, Y
    Kumagai, H
    Kostin, S
    Schaper, J
    Nakazawa, M
    Ozawa, K
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (19) : 7381 - 7385
  • [19] Mutations in the human δ-sarcoglycan gene in familial and sporadic dilated cardiomyopathy
    Tsubata, S
    Bowles, KR
    Vatta, M
    Zintz, C
    Titus, J
    Muhonen, L
    Bowles, NE
    Towbin, JA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (05) : 655 - 662
  • [20] Molecular normalization of dystrophin in the failing left and right ventricle of patients treated with either pulsatile or continuous flow-type ventricular assist devices
    Vatta, M
    Stetson, SJ
    Jimenez, S
    Entman, ML
    Noon, GP
    Bowles, NE
    Towbin, JA
    Torre-Amione, G
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (05) : 811 - 817